ES2914280T3 - Medicine for use in the treatment of gout - Google Patents

Abstract

A medicament for use in the treatment of gout, characterized in that the medicament comprises by weight, 1-99 parts of a seaweed glycoprotein, 8-14 parts of indigo naturalis and 7-13 parts of achyranthes root two teeth.

Description

DESCRIPTION

Medicine for use in the treatment of gout

technical field

The present invention relates to a medicament for use in the treatment of gout, and belongs to the technical field of medical technology.

prior art

Gout is a disease caused by a disorder of purine metabolism. Its clinical manifestations are characteristic acute arthritis, goofy formation, and chronic gouty arthritis caused by hyperuricemia and urate crystal deposition, patients may experience urate nephropathy and uric acid-related urinary stones; in severe cases, patients may experience joint disability and kidney failure. The prerequisite for the onset of gout is hyperuricemia. Therefore, hyperuricemia is the most important biochemical basis for gout, followed by the inflammatory response caused by urate deposition. With the improvement of people's living standards, the incidence of hyperuricemia and primary gout has been increasing year by year, due to changes in dietary structure, especially the increase in alcohol, especially beer, as well as such as decreased physical activity; the age of onset is getting younger. Since uric acid is supersaturated in the blood, in addition to direct damage to bones and joints, it will also be deposited in the kidneys, leading to kidney disease, which poses a greater risk to human health and has drawn attention widespread in the medical community.

Western medicine currently treats hyperuricemia and gout in stages. Western medicine commonly uses nonsteroidal anti-inflammatory drugs (such as etoricoxb, celecoxib), uric acid-lowering drugs (such as allopurinol, febuxostat, probenecid, and benzbromarone), glucocorticoids, and colchicine, etc., during the acute phase; As for treatments during intermittent and chronic stages, patients are often treated with dietary control and uric acid lowering drugs; Although non-steroidal anti-inflammatory drugs can quickly control the polar attack of gout, the drug only exerts an analgesic function during the initial stage of gout, but pain relief does not cure the disease; treatment only focuses on relieving symptoms and ignores root cause removal, and these drugs have serious toxicity.

Patent: ASTER GLEHNI EXTRACTS, FRACTIONS OR ISOLATED COMPOUNDS THEREOF FOR THE TREATMENT OR PREVENTION OF HYPERURICEMIA OR GOUT, the patent number is US-2015337001 (A1), it is described that: the invention refers to anaster glehni extract, capable of preventing and improving hyperuricemia or gout, with the effect of inhibiting the production of uric acid and reducing its concentration.

Patent: THE USE OF BUCILLAMINA IN THE TREATMENT OF GOUT, patent no. US-2015306054 (A1), it is described that: pharmaceutical compositions comprising, bucillamine, including bucillamine and allopurinol or colchicine, or pharmaceutically acceptable salts or solvates thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients are described. Methods for the use of said compositions in the treatment of gout and metabolic syndrome are also disclosed.

Patent: a traditional Chinese medicinal composition for treating gout, patent no. CN201310601617.4, it is described that: A traditional Chinese medicinal composition for treating gout refers to a traditional Chinese medicinal composition. The invention aims to solve the problem that the western medicine has many side effects on the human body in the treatment of gout, and the treatment focuses only on symptom relief, and ignores the removal of the root cause. . The traditional Chinese medicinal composition for treating gout herein comprises, by weight, 5-10 parts of sophora flavescens, 10-15 parts of epimedium, 5-10 parts of prepared aconite root, 4-8 parts of ligusticum wallichii , 8-12 parts of pyrrosia lingua, 6-9 parts of papaya and 3-6 parts of fructus amomi. The traditional Chinese medicinal composition for treating gout has little side effects on the human body, and is capable of relieving symptoms and eliminating the root cause, with an overall clinical response rate of 96.7%. The invention is used for the treatment of gout.

JP 2010 235517 A describes a material for the prophylaxis of lifestyle-related diseases, which contains the material treated with chlorella protease as an active ingredient. The material for the prophylaxis of lifestyle-related diseases improves either adiposis, hyperlipemia (a neutral fat or a free fatty acid) or hyperglycemia, and has any of an insulin sensitivity-improving action, an action of improvement of liver function (GPT), or an action of improvement of kidney function (uric acid). Furthermore, since lifestyle-related diseases can be prevented by ingestion of a small amount, the material is suitable for daily ingestion over long periods, particularly as food.

EP-1 506 785 A1 describes a composition for treating or preventing hyperuricemia, which contains chondroitin sulfate protein complex as an effective ingredient. Because it has a serum uric acid level lowering effect, this composition allows to provide a novel method of gout treatment, prevention and relief.

CN 101 002 873 A describes special marine foods, especially for patients with hyperuricemia. The marine food is characterized by being prepared by taking food-derived marine bioactive polysaccharides as main raw materials, adding seaweed powder, and mixing the food-derived marine bioactive polysaccharides and seaweed powder, with the auxiliary materials including nutritional amino acids, oligosaccharides, vitamins and minerals. Sea food can be powdered or granulated, and is taken after dissolving it in hot water. Marine food is easy to dissolve, has maximum biological absorbance and maximum bioavailability in human bodies, provides marine active factors and nutritional components for human bodies, supplements various essential vitamins and minerals for human bodies, is beneficial in improving the nutritional status of hyperuricemia patients and can help reduce uric acid level and control hyperuricemia level, improve human bodies' immunity and prevent gout by the synergy of such factors as bioactive components in derived marine bioactive polysaccharides of food, seaweed powder, nutritional amino acids and the like, thus being suitable for patients with hyperuricemia.

US-2010/048507 A1 describes a food/beverage or pharmaceutical composition for oral administration to improve an acidic urine, comprising fucoidan or a fucoidan-containing material as an active ingredient, characterized in that a urinary pH is persistently increased; use of fucoidan, or a material containing fucoidan, for the production of the food/beverage or the pharmaceutical composition for oral administration; and a method of improving acidic urine by persistently increasing a patient's urinary pH, comprising orally administering fucoidan, or a fucoidan-containing material, to a patient.

The mechanism of action of traditional Chinese medicine to treat gout is complicated, and the clinical efficacy is unclear. At present, there is no clinically recommended Chinese patent medicine to treat gout, and Western domestic gout patients practically rely on Western medicine for treatment.

Content of the invention

The present invention provides a medicament for use in the treatment of gout in order to overcome the deficiencies in the prior art in order to achieve the following objectives thereof:

(1) The medicament of the present specification has the characteristics of high efficiency, safety and no side effects, and has a good therapeutic effect on human gout, with a total effective rate of 98% and a low recurrence rate.

(2) The present medicament reduces urine protein content in gout rat model;

(3) The present medicament reduces creatinine content in gout rat model;

(4) The present medicament reduces the urea nitrogen content in the gout rat model;

(5) The present medicament reduces the uric acid content in the blood in the mouse model of hyperuricemia.

The present invention is defined in the appended claims.

Compared with the prior art, the advantages of the present invention are:

(1) The medicament of the present specification has a significant therapeutic effect on human gout, with a total effective rate of 98%, of which the good cure rate is 85%, the marked efficacy rate is 13% and the failure rate is only 2%. For cured patients, the 5-year recurrence rate is only 1%;

(2) The present medicament reduces urine protein content in gout rat model; after four weeks of administration of the gouty rat model, the urine protein value of the rat is 50.89-168.78 mg/L; the urine protein value of the rat in the control group of the model is 364.83 mg/L;

(3) The present medicament reduces creatinine content in gout rat model; after four weeks of administration of the gout rat model, the creatinine value of the rat is 152.45-172.82 mg/L; the creatinine value of the rat in the control group of the model is 288.01 mmol/L; (4) The present medicament reduces the urea nitrogen content in the gout rat model; after four weeks of administration of the gouty rat model, the rat urea nitrogen value is 11.58-15.64 mmol/L; the urea nitrogen value in the model control group is 56.07 mmol/L; (5) The present medicament reduces the uric acid content in the blood in the mouse model of hyperuricemia; the mice administered with the medicament in the invention have a blood uric acid value of 147.89-160.5 pmol/L; mice in the control group of the model have a blood uric acid value of 250.4 pmol/L.

Specific realizations

In the present memory it is described:

Embodiment 1 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

Seaweed glycoprotein comprises, by weight content, 1% sugar and 99% protein; The molecular weight is 0.2 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 2 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

Seaweed glycoprotein comprises, by weight content, 9% sugar and 88% protein; The molecular weight is 3 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 3 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

Seaweed glycoprotein comprises, by weight content, 16% sugar and 80% protein; The molecular weight is 25 kDa;

Said sugar is a polysaccharide;

Said seaweed is chlorella;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 4 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

Seaweed glycoprotein comprises, by weight content, 30% sugar and 70% protein; The molecular weight is 40 kDa;

Said sugar is a polysaccharide;

Said marine algae are red algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 5 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

The seaweed glycoprotein comprises, by weight content, 50% sugar and 50% protein; The molecular weight is 100 kDa;

Said sugar is a polysaccharide;

Said marine algae are brown algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 6 A medicament for use in the treatment of gout (not covered by the claims) Wherein the medicament is a seaweed glycoprotein;

The seaweed glycoprotein comprises, by weight content, 99% sugar and 1% protein; The molecular weight is 3000 kDa;

Said sugar is a polysaccharide;

Said seaweeds are golden algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

The glycoprotein mentioned in these above embodiments 1-6 further includes a pigment; said pigment is a natural pigment contained in seaweed substances;

These embodiments 1-6 above could be summarized as:

A medicine for use in the treatment of gout

Said drug is a glycoprotein;

The glycoprotein comprises, by weight content, 1-99% sugar and 1-99% protein;

The molecular weight is 0.2-30,000 kDa;

Said sugar is a polysaccharide;

Said medicament includes synthetic glycoproteins, and synthetic polysaccharides and proteins.

Said protein comprises 20 kinds of amino acids and 8 kinds of synthetic amino acids; The method of preparation of said drug; glycoprotein, is made into capsules and tablets, etc., according to a conventional process; the polysaccharide and protein mixture is prepared into capsules and tablets, etc., according to a conventional process.

Embodiment 7 Application of said medicament in the treatment of gout (not covered by the claims)

( 1) Therapeutic effect of the drug in the present invention on the streptozotocin-induced gout rat model

In the control groups of the model and the groups of the invention, streptozotocin was first used to induce gout in rats, and then the rats in the groups of the invention were administered the medicine prepared by the present invention and they were administered intragastrically three times a day; the rats in the control group were administered the distilled water, and the value of urine protein, and the content of creatinine and urea nitrogen were measured four weeks later, with the results shown in Table 1 and Table 1. Table 2.

Table 1 Effect of the drug in the rat model of streptozotocin-induced gout

Table 2 Effect of the drug, at different doses, in the rat model with gout induced by streptozotocin

( 2) Therapeutic effect of the drug in the mouse model of xanthine-induced hyperuricemia

A. Experimental Materials

Animals: 50 clean-grade Kunming mice, male, 20 g ± 2 g

Drug: the drug described in Embodiments 1-6

Xanthine: Sinopharm Chemical Reagent Co., Ltd., lot number of WL20101109

Blood uric acid test kit: Shanghai Rongsheng Biotech Co., Ltd., batch number of 20100406 B. Experimental method

Mice were randomly divided into 8 groups after entering the laboratory, namely normal control group, model control group and groups 1-6 of the present invention, 10 rats in each group, weighed and numbered;

After one week of adaptive feeding, mice in the normal control group and model control group were given distilled water by intragastric administration, and mice 1-6 in the invention group were given the medicament in the present invention in a dose of 3 g/day, administered intragastrically, three times a day for three consecutive days.

One hour after the last intragastric administration, mice in the normal control group were injected intraperitoneally with a 0.1 ml/10 g normal saline solution, and mice in the other 7 groups were injected intraperitoneally. intraperitoneally a 10% xanthine suspension 0.1 ml/10 g for modeling. After 0.5 h, blood was taken by the eyeball removal method, the uric acid value was measured, and the measurement results were statistically analyzed. The results are shown in Table 3.

Table 3 Effect of the drug on blood uric acid in the mouse model of hyperuricemia

Table 4 Effect of the drug at different doses on blood uric acid in the mouse model of hyperuricemia

Human clinical trials are as follows:

A total of 100 cases were included, 52 males and 48 females, with ages ranging from 32 years to 61 years of age, with a disease duration ranging from 6 months to 8 years, mainly from 3 to 5 years; such as inflammation and pain of the first metatarsophalangeal joint, 50 cases had unilateral involvement and 50 cases had bilateral involvement; where 60 cases of unilateral arthritis, 40 cases of pain and inflammation affecting bilateral joints, and where 10 cases of the presence of arthritic stones. All cases passed the test and all 100 cases had an increase in uric acid in their blood. For all of them, the possibility that it was caused by medications or other diseases was ruled out. Treatment methods:

All the medicine for gout treatment in Embodiment 3 was administered at 3 g per day, 3 times, 3 times per day, to be taken after mixing with hot boiled water. 21 days a treatment process was maintained, generally, a treatment process was needed, and the efficacy was observed at the end of the treatment. Efficacy evaluation criteria:

Healing: all clinical symptoms disappeared, joints were able to move freely, uric acid in the blood decreased to a value within the normal range; marked efficacy: clinical symptoms improved, joint activity was flexible, and uric acid in the blood decreased by more than 10%; no response: no change in symptoms and laboratory test indicators.

Results:

Cured: 85 cases, representing 85%;

Marked efficiency: 13 cases, representing 13%;

No response: 2 cases, representing 2%;

Total effective rate: 98%;

The recurrence rate is low, and as for cured patients, the 5-year recurrence rate is only 1%. Embodiment 8 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

1 part seaweed glycoprotein and 1 part glucuronic acid;

Seaweed glycoprotein comprises, by weight content, 9% sugar and 88% protein; The molecular weight is 8 kDa;

Said sugar is a polysaccharide;

Said marine algae are spirulina;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 9 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

15 parts of seaweed glycoprotein and 6 parts of glucuronic acid;

Seaweed glycoprotein comprises, by weight content, 9% sugar and 88% protein; The molecular weight is 12 kDa;

Said sugar is a polysaccharide;

Said seaweed is chlorella;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 10 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

40 parts of seaweed glycoprotein and 13 parts of glucuronic acid;

Seaweed glycoprotein comprises, by weight content, 30% sugar and 70% protein; The molecular weight is 20 kDa;

Said sugar is a polysaccharide;

Said seaweeds are Bangiaatropurpurea(Roth)C.Agardh;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 11 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

70 parts of seaweed glycoprotein and 17 parts of glucuronic acid;

The seaweed glycoprotein comprises, by weight content, 50% sugar and 50% protein; The molecular weight is 8 kDa;

Said sugar is a polysaccharide;

These seaweeds are sargassum;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 12 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

99 parts of seaweed glycoprotein and 25 parts of glucuronic acid;

The seaweed glycoprotein comprises, by weight content, 99% sugar and 1% protein; The molecular weight is 20 kDa;

Said sugar is a polysaccharide;

Said seaweeds are sinuraceae urelina;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 13 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

1 part seaweed glycoprotein, 1 part glucuronic acid and 2 parts indigo naturalis;

Seaweed glycoprotein comprises, by weight content, 9% sugar and 88% protein; The molecular weight is 6 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 14 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

27 parts seaweed glycoprotein, 6 parts glucuronic acid, and 4 parts indigo naturalis;

Seaweed glycoprotein comprises, by weight content, 9% sugar and 88% protein; The molecular weight is 20 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 15 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

52 parts seaweed glycoprotein, 14 parts glucuronic acid, and 5 parts indigo naturalis;

Seaweed glycoprotein comprises, by weight content, 30% sugar and 70% protein; The molecular weight is 200 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 16 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

99 parts seaweed glycoprotein, 25 parts glucuronic acid, and 9 parts indigo naturalis;

The seaweed glycoprotein comprises, by weight content, 50% sugar and 50% protein; The molecular weight is 3000 kDa;

Said sugar is a polysaccharide;

Said marine algae are blue-green algae;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Application of said medicine in Embodiment 8 - Embodiment 16 in the treatment of gout Using the test method said in Embodiment 7, the medicine said in Embodiment 8 - Embodiment 16 in these groups of the invention, has the following effects of app:

( 1) Effects of the drug in the rat model of streptozotocin-induced gout

Table 5 Drug Effects in the Streptozotocin-Induced Gout Rat Model

( 2) Therapeutic effect of the drug in the mouse model of xanthine-induced hyperuricemia Table 6 Effect of the drug in the mouse model with hyperuricemia

( 3) Human clinical trials

Results:

Cured: 88 cases, representing 88%;

Marked efficiency: 10 cases, representing 10%;

No response: 2 cases, representing 2%;

Total effective rate: 98%;

The recurrence rate is low, and as for cured patients, the 6-year recurrence rate is only 1%. Embodiment 17 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

1 part seaweed glycoprotein, 8 parts indigo naturalis and 7 parts two-cloves achyranthes root;

The seaweed glycoprotein comprises, by weight content, 10% sugar and 85% protein; The molecular weight is 16 kDa;

Said sugar is a polysaccharide;

Said marine algae are spirulina;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 18 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

40 parts of seaweed glycoprotein, 11 parts of indigo naturalis and 9 parts of two-toothed achyranthes root; The seaweed glycoprotein comprises, by weight content, 8% sugar and 88% protein; The molecular weight is 14 kDa;

Said sugar is a polysaccharide;

Said seaweed is chlorella;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 19 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

99 parts seaweed glycoprotein, 14 parts indigo naturalis and 13 parts two-toothed achyranthes root;

Seaweed glycoprotein comprises, by weight content, 30% sugar and 70% protein; The molecular weight is 38 kDa;

Said sugar is a polysaccharide;

Said marine algae are Gelidium amansii Lamx;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 20 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

1 part seaweed glycoprotein, 8 parts indigo naturalis, 7 parts two-toothed achyranthes root, and 1 part glucuronic acid;

The seaweed glycoprotein comprises, by weight content, 10% sugar and 85% protein; The molecular weight is 16 kDa;

Said sugar is a polysaccharide;

Said marine algae are spirulina;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Embodiment 21 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

40 parts of seaweed glycoprotein, 11 parts of indigo naturalis, 9 parts of the two-toothed achyranthes root, and 8 parts of glucuronic acid;

The seaweed glycoprotein comprises, by weight content, 8% sugar and 88% protein; The molecular weight is 14 kDa;

Said sugar is a polysaccharide;

Said seaweed is chlorella;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Realization 22 A medicament for use in the treatment of gout

It comprises, based on weight, the following components:

99 parts of seaweed glycoprotein, 14 parts of indigo naturalis, 13 parts of two-toothed achyranthes root, and 15 parts of glucuronic acid;

Seaweed glycoprotein comprises, by weight content, 30% sugar and 70% protein; The molecular weight is 200 kDa;

Said sugar is a polysaccharide;

Said marine algae are Gelidium amansii Lamx;

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

Application of said medicine in Embodiment 17 - Embodiment 22 in the treatment of gout

Using the test method said in Embodiment 7, the medicine said in Embodiment 17-Embodiment 22 in these groups of the invention, has the following application effects:

( 1) Effects of the drug in the present invention in the streptozotocin-induced gout rat model Table 7 Effects of the drug in the present invention in the streptozotocin-induced gout rat model

( 2) Therapeutic effect of the drug in the present invention in the mouse model of xanthine-induced hyperuricemia

Table 8 Effect of the drug in the present invention in the mouse model of hyperuricemia

( 3) Human clinical trials

Results:

Cured: 90 cases, representing 90%;

Marked efficiency: 9 cases, representing 9%;

No response: 1 case, representing 1%;

Total effective rate: 99%;

The recurrence rate is low and, as for cured patients, no recurrence was observed in 5 years.

Embodiment 23 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

Seaweed glycoprotein 80 parts, Radiax sophorae flavescentis 10 parts, Radices saussureae 5 parts, Rhododendron mariae 5 parts, Unispike kyllinga grass 7 parts, Fructus evodiae 8 parts, Pyrola grass 10 parts;

The seaweed glycoprotein comprises, by weight content, 10% sugar and 85% protein; The molecular weight is 15 kDa;

Said marine algae are green algae;

Said sugar, by weight, comprises the following components: 8 parts of glucose, 5 parts of galactose and 11 parts of carubinose;

The above protein, by weight, includes the following components: 7 parts serine, 9 parts threonine, and 15 parts hydroxylysine.

Embodiment 24 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

75 parts seaweed glycoprotein, 12 parts epimedium, 8 parts nutmeg, 7 parts gall, 9 parts radix aconti lateralis preparata, 6 parts gastrodia elata and 5 parts caulis sinomenii; The seaweed glycoprotein comprises, by weight content, 12% sugar and 75% protein; The molecular weight is 8 kDa;

Said marine algae are blue-green algae;

Said sugar, by weight, comprises the following components: 20 parts of glucose, 8 parts of galactose and 15 parts of carubinose;

The above protein, by weight, includes the following components: 10 parts serine, 15 parts threonine, and 17 parts hydroxylysine.

Embodiment 25 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

70 parts seaweed glycoprotein, 8 parts monkshood, 6 parts dolichoris semen, 5 parts bombyx batryticatus, 3 parts pinellia ternata, 7 parts atacilolodes rhizome, and 8 parts pubescent angelica root; The seaweed glycoprotein comprises, by weight content, 14% sugar and 72% protein; The molecular weight is 20 kDa;

Said marine algae are blue-green algae;

Said sugar, by weight, comprises the following components: 20 parts of glucose, 8 parts of galactose and 15 parts of carubinose;

The above protein, by weight, includes the following components: 10 parts serine, 15 parts threonine, and 17 parts hydroxylysine.

Embodiment 26 A medicament for use in the treatment of gout (not covered by the claims) Comprises, on a weight basis, the following components:

78 parts of seaweed glycoprotein, 10 parts of ligusticum wallichii, 8 parts of alismatis rhizome, 6 parts of cimicifuga foetida, 7 parts of pittosporum glabrousleaf, 7 parts of notoperigium root and 5 parts of Chinese clematis root;

The seaweed glycoprotein comprises, by weight content, 22% sugar and 69% protein; The molecular weight is 100 kDa;

Said marine algae are blue-green algae;

Said sugar, by weight, comprises the following components: 20 parts of glucose, 8 parts of galactose and 15 parts of carubinose;

The above protein, by weight, includes the following components: 10 parts serine, 15 parts threonine, and 17 parts hydroxylysine.

Embodiment 27 A medicament for use in the treatment of gout (not covered by the claims) Stage 1: Weigh-in

Weigh the seaweed glycoprotein and all components of Chinese medicine, according to the formula;

Stage 2: Chinese Medicine Extraction

(1) Wash

Wash all components of Chinese medicine with clear water and remove impurities;

(2) Shock and microwave extraction

Chinese medicine is pulverized into 100 mesh medicinal material powder, 50% ethanol is added 8 times, the temperature is controlled at 60 °C, microwave radiation is carried out at the microwave power of 260 W, length microwave wave of 130 mm, a frequency of 1200 MHz for 5 min, then filtration is carried out, and finally the filtrate is collected;

The medicine sediments are separated, 6 times of clear water is added, the temperature is controlled at 50 °C, microwave radiation is carried out at the microwave power of 200 W, microwave wavelength of 140 mm, a frequency of 1250 MHz for 5 min, then filtration is carried out, and finally the filtrate is collected;

Combine the filtrate collected from the two procedures; spray and dry to make them into Chinese medicine powder;

Step 3 Add seaweed glycoprotein.

Mix the seaweed glycoprotein powder with the Chinese medicine powder prepared above, to produce different dosage forms, such as capsules, tablets and so on.

Application of said medicine in Realization 23-Realization 26 in the treatment of gout

Apply the test method specified in Embodiment 7, this group of the invention is the medicine mentioned in Embodiment 23-Embodiment 26, the applicable effects are as follows:

( 1) Drug Effects in Streptozotocin-Induced Gout Rat Model Table 9 Drug Effects in Streptozotocin-Induced Gout Rat Model

( 2) Therapeutic effect of the drug in the mouse model of xanthine-induced hyperuricemia Table 10 Effect of the drug in the mouse model of hyperuricemia

( 3) Human clinical trials

Results:

Cured: 90 cases, representing 90%;

Marked efficiency: 9 cases, representing 9%;

No response: 1 case, representing 1%;

Total effective rate: 99%;

The recurrence rate is low and, as for cured patients, no recurrence was observed in 5 years. For the medicament mentioned in this invention, a pH between 5.3-9.8 and 6.5-7.5 is preferred.

The invention has undergone a large number of experiments, and we have carried out multiple tests using a mixture of seashells, bones of cattle and poultry, a mixture of glycoprotein, polysaccharides and proteins extracted from the skeleton of marine animals, and the objects of the invention have also been achieved.

Embodiment 28 A medicament for use in the treatment of gout (not covered by the claims) Said medicament is a mixture of polysaccharides and proteins;

Said medicament comprises, by weight content, 1-99% polysaccharide and 1-99% protein.

Said polysaccharide comprises: glucose, galactose, mannose and rhamnose;

Said protein comprises: arginine, lysine, serine and threonine.

As for said mixture of polysaccharide and protein, the polysaccharide has a molecular weight of 0.2-3000 kDa and the protein has a molecular weight of 0.2-3000 kDa.

The mixture of polysaccharides and proteins, in addition, a mixture of algal polysaccharides and algal proteins;

Said mixture of algal polysaccharide and algal protein also comprises a pigment;

Said pigment is a natural pigment contained in algae substance;

Said algal protein may be algal phycocyanin, phycoerythrin or xanthoprotein.

Said glycoprotein includes synthetic glycoprotein, polysaccharide and synthetic protein.

The medicament mentioned in this invention has a No Observed Adverse Effect Level (NOAEL) of 1.6 g/kg during a 12-week oral administration for dogs, which is equivalent to 50 times the equivalent dose. for human beings, so it is concluded that the safety of the clinical trial can be guaranteed.

The medicine described in this invention can also be a health care product or a food.

Claims (5)

Yo. A medicament for use in the treatment of gout, characterized in that the medicament comprises by weight, 1-99 parts of a seaweed glycoprotein, 8-14 parts of indigo naturalis and 7-13 parts of achyranthes root two teeth. 2. The medicament for use in the treatment of gout according to claim 1, further comprising 1-15 parts of glucuronic acid. 3. The medicament for use in treating gout according to claim 1, wherein said seaweed glycoprotein comprises, by weight content, 1-99% sugar and 1-99% protein. 4. The medicament for use in treating gout according to claim 1, wherein a molecular weight of the seaweed glycoprotein is 0.2 to 3000 kDa. 5. The medicament for use in treating gout according to claim 1, wherein the algae comprise one or more types of blue-green algae, green algae, red algae, golden algae and brown algae.